BACKGROUND: The ATM kinase constitutes a master regulatory hub of DNA damage and activates the p53 response pathway by phosphorylating the MDM2 protein, which develops an affinity for the p53 mRNA secondary structure. Disruption of this interaction prevents the activation of the nascent p53. The link of the MDM2 protein-p53 mRNA interaction with the upstream DNA damage sensor ATM kinase and the role of the p53 mRNA in the DNA damage sensing mechanism, are still highly anticipated. METHODS: The proximity ligation assay (PLA) has been extensively used to reveal the sub-cellular localisation of the protein-mRNA and protein-protein interactions. ELISA and co-immunoprecipitation confirmed the interactions in vitro and in cells. RESULTS: This study provides a novel mechanism whereby the p53 mRNA interacts with the ATM kinase enzyme and shows that the L22L synonymous mutant, known to alter the secondary structure of the p53 mRNA, prevents the interaction. The relevant mechanistic roles in the DNA Damage Sensing pathway, which is linked to downstream DNA damage response, are explored. Following DNA damage (double-stranded DNA breaks activating ATM), activated MDMX protein competes the ATM-p53 mRNA interaction and prevents the association of the p53 mRNA with NBS1 (MRN complex). These data also reveal the binding domains and the phosphorylation events on ATM that regulate the interaction and the trafficking of the complex to the cytoplasm. CONCLUSION: The presented model shows a novel interaction of ATM with the p53 mRNA and describes the link between DNA Damage Sensing with the downstream p53 activation pathways; supporting the rising functional implications of synonymous mutations altering secondary mRNA structures.

Department of Medical Biosciences Umeå University Umeå 90185 Sweden

Inserm UMRS1131 Institut de Génétique Moléculaire Paris Cité Université Hôpital St Louis Paris France

Institut de Biotecnologia 1 de Biomedicina Universitat Autònoma de Barcelona Bellaterra Spain

Research Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute Brno Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc24007529

003      

CZ-PrNML

005      

20240423160034.0

007      

ta

008      

240412s2024 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1186/s12943-024-01933-z $2 doi

035    __

$a (PubMed)38263180

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Karakostis, Konstantinos $u Inserm UMRS1131, Institut de Génétique Moléculaire, Paris Cité Université, Hôpital St. Louis, Paris, France. konstantinos.karakostis@gmail.com $u Institut de Biotecnologia I de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra (Barcelona), Spain. konstantinos.karakostis@gmail.com

245    14

$a The DNA damage sensor ATM kinase interacts with the p53 mRNA and guides the DNA damage response pathway / $c K. Karakostis, L. Malbert-Colas, A. Thermou, B. Vojtesek, R. Fåhraeus

520    9_

$a BACKGROUND: The ATM kinase constitutes a master regulatory hub of DNA damage and activates the p53 response pathway by phosphorylating the MDM2 protein, which develops an affinity for the p53 mRNA secondary structure. Disruption of this interaction prevents the activation of the nascent p53. The link of the MDM2 protein-p53 mRNA interaction with the upstream DNA damage sensor ATM kinase and the role of the p53 mRNA in the DNA damage sensing mechanism, are still highly anticipated. METHODS: The proximity ligation assay (PLA) has been extensively used to reveal the sub-cellular localisation of the protein-mRNA and protein-protein interactions. ELISA and co-immunoprecipitation confirmed the interactions in vitro and in cells. RESULTS: This study provides a novel mechanism whereby the p53 mRNA interacts with the ATM kinase enzyme and shows that the L22L synonymous mutant, known to alter the secondary structure of the p53 mRNA, prevents the interaction. The relevant mechanistic roles in the DNA Damage Sensing pathway, which is linked to downstream DNA damage response, are explored. Following DNA damage (double-stranded DNA breaks activating ATM), activated MDMX protein competes the ATM-p53 mRNA interaction and prevents the association of the p53 mRNA with NBS1 (MRN complex). These data also reveal the binding domains and the phosphorylation events on ATM that regulate the interaction and the trafficking of the complex to the cytoplasm. CONCLUSION: The presented model shows a novel interaction of ATM with the p53 mRNA and describes the link between DNA Damage Sensing with the downstream p53 activation pathways; supporting the rising functional implications of synonymous mutations altering secondary mRNA structures.

650    _2

$a lidé $7 D006801

650    12

$a polynukleotid-5'-hydroxylkinasa $7 D011116

650    12

$a protoonkogenní proteiny c-mdm2 $7 D051736

650    _2

$a nádorový supresorový protein p53 $7 D016159

650    _2

$a poškození DNA $7 D004249

650    _2

$a oprava DNA $7 D004260

650    _2

$a ATM protein $7 D064007

655    _2

$a dopisy $7 D016422

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Malbert-Colas, Laurence $u Inserm UMRS1131, Institut de Génétique Moléculaire, Paris Cité Université, Hôpital St. Louis, Paris, France

700    1_

$a Thermou, Aikaterini $u Inserm UMRS1131, Institut de Génétique Moléculaire, Paris Cité Université, Hôpital St. Louis, Paris, France

700    1_

$a Vojtesek, Borek $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic

700    1_

$a Fåhraeus, Robin $u Inserm UMRS1131, Institut de Génétique Moléculaire, Paris Cité Université, Hôpital St. Louis, Paris, France. robin.fahraeus@inserm.fr $u Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic. robin.fahraeus@inserm.fr $u Department of Medical Biosciences, Umeå University, Umeå, 90185, Sweden. robin.fahraeus@inserm.fr

773    0_

$w MED00008245 $t Molecular cancer $x 1476-4598 $g Roč. 23, č. 1 (2024), s. 21

856    41

$u https://pubmed.ncbi.nlm.nih.gov/38263180 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20240412 $b ABA008

991    __

$a 20240423160031 $b ABA008

999    __

$a ok $b bmc $g 2081496 $s 1217296

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2024 $b 23 $c 1 $d 21 $e 20240123 $i 1476-4598 $m Molecular cancer $n Mol Cancer $x MED00008245

GRA    __

$a project no. 23-06884S $p Czech Science Foundation

GRA    __

$a MH CZ - DRO (MMCI, 00209805) $p Grantová Agentura České Republiky

LZP    __

$a Pubmed-20240412